FineHeart and the EIC Accelerator: A Wireless Heart Pump Advances
FineHeart, founded in 2010 in Pessac near Bordeaux, makes FlowMaker, an implantable pump that sits in the heart, synchronises with its natural contractions and is powered wirelessly. The company says it needs no external driveline, unlike current heart assist devices, and its EIC project said 95% of patients with severe heart failure are "left without any solution", according to CORDIS.
The European Innovation Council granted €2,500,000 towards a €9.9 million project from October 2022 to March 2025, which aimed to "conduct the clinical trials to enter the EU market in 2026, then the US market". The final report says the first implantation in a human was completed, more than 50 clinical-grade devices were made and the technology moved from readiness level 5 to 8. The first implants took place at IKEM in Prague in 2024, according to FineHeart's announcement. In 2025 it won approval for studies in France and Slovenia, and in January 2026 it announced €83 million: a €35 million first closing of a Series C and €48 million in IPCEI grants to be paid in tranches. Sources reviewed on 4 November 2026 do not show an application for EU market approval (CE marking).
Company file
- Legal entity
- FineHeart SA, SIREN 519 375 356, Pessac
- Founded
- 2010
- CEO and co-founder
- Arnaud Mascarell
- CSO and co-founder
- Stéphane Garrigue
- Product
- FlowMaker (ICOMS) intracardiac pump
- IP
- 27 patent families, 160 patents, according to the company (January 2026)
- EIC project
- FLOWMAKER, 1 Oct 2022 to 31 Mar 2025
Where FineHeart Stands Now
France's medicines agency ANSM authorised a multi-centre first-in-human study in June 2025, led by Pascal Leprince at Pitié-Salpêtrière, and Slovenia's JAZMP followed in July. In July 2025 FineHeart was named lead partner of IPCEI Tech4Cure, an Important Project of Common European Interest for medical devices that the European Commission approved on 22 July 2025 with up to €403 million of state aid from five member states. The January 2026 announcement combined a €35 million first closing of a Series C, with new investors Groupe Pasteur Mutualité and Groupe Etchart and what FineHeart called significant participation from the EIC's fund, and €48 million in IPCEI grants to be disbursed in several tranches. At the end of 2024, before this money, FineHeart's equity was negative at minus €5.88 million, according to Pappers.
The record
A wireless heart pump reaches its first patients
FineHeart implanted its FlowMaker in its first patients in Prague in 2024, won approval for trials in Slovenia and France in 2025, and announced €83M in equity and grants in January 2026.
- 2010Company foundedPessac, near Bordeaux
- Jun 2022EIC Accelerator cut-offFLOWMAKER: implantable pump for severe heart failureblended finance
- Oct 2022EIC project starts€9.9M project€2.50M grant
- 2024First implantsIKEM, Prague; results presented November 2024
- Mar 2025EIC project endsTRL 8; over 50 clinical-grade devices made
- Jun-Jul 2025Trial approvalsFrance (ANSM) and Slovenia (JAZMP)
- Jul 2025IPCEI Tech4Cure leadCommission-approved, up to €403M state aid from five member states
- Jan 2026Funding€35M first Series C close plus €48M IPCEI grants in tranches€83M
FineHeart, CORDIS and Pappers.
"This crucial achievement allows us to realize FineHeart's vision."
Arnaud Mascarell, CEO and co-founder, FineHeart, November 2024, on the first implantsThe Technology: A Pump Inside the Heart
According to the company, FlowMaker was implanted in Prague on a beating heart, without stopping it, and unlike other devices it needs no bypass to the aorta; its compact size and low energy use allow wireless power. The trial in France is designed to assess safety, implant feasibility and preliminary performance. FineHeart says first results were presented at an EACTS summit in November 2024, but its releases give no patient numbers or outcome data, and the sources reviewed on 4 November 2026 do not include a peer-reviewed publication.
The money
The January 2026 financing
In € millions. FineHeart said the €83M total combines a €35M first closing of its Series C and €48M in IPCEI Tech4Cure grants to be disbursed in several tranches; amounts received are not disclosed.
FineHeart, January 2026.
What the EIC Project Promised, and What CORDIS Shows
The EIC project
EU contribution covers 25% of a €9.9M project
FLOWMAKER ran from October 2022 to March 2025. CORDIS lists it as closed; the remainder is other project costs, not proof of company cash.
CORDIS project 190146685. Values in € millions.
The project promised the clinical trials needed to enter the EU market in 2026. It delivered the first human implants, manufacturing of clinical devices and regulatory approvals for multi-centre studies, and FineHeart plans to expand production space from 1,200 to 3,500 square metres. The trials that would support an EU application were only authorised after the project ended, and the final report itself targets European regulatory approval in 2027. CORDIS lists the project as closed.
- First-in-human implantsDeliveredPrague, 2024.
- Clinical manufacturingDelivered50+ devices.
- Multi-centre trialsAuthorisedFrance, Slovenia, 2025.
- EU market in 2026Not on trackFinal report targets 2027.
The Money
FineHeart lost €6.19 million in 2022, €8.21 million in 2023 and €7.65 million in 2024, and its equity fell from €10.7 million to minus €5.88 million over those years. The EIC grant covered a quarter of the project. The 2026 financing changes that picture: FineHeart says €35 million is Series C equity from named new and existing investors and €48 million is IPCEI grants paid in tranches, but it has not disclosed each investor's share or how much of the grant has been received.
The accounts
Losses turned equity negative by 2024
€ thousands at year end, before the January 2026 financing.
Pappers, FineHeart SA (519 375 356).
What Cannot Be Checked
Questions for the EIC
How many patients have received FlowMaker and how they have fared, how much the EIC fund and each other investor put into the Series C, and how much of the €48 million IPCEI grant has been paid are not public.
Why Europe Should Care
The EIC project spoke of "EU sovereignty in severe heart failure treatment", and FineHeart is now lead partner in an IPCEI for medical devices backed by state aid from five member states. It has taken its pump into patients; whether it works over time is what the trials authorised in 2025 will show.
What the project promised
Clinical trials to enter the EU market in 2026 with a fully implantable, wireless heart pump.
What the record shows
First implants in Prague, trial approvals in two countries, €83 million announced and no EU approval yet.
The Verdict
In patients, not yet on the market
FineHeart's device is in patients and the company has announced substantial funding. The 2026 market entry it promised the EIC is not supported by any published trial result, and its final EIC report now targets European approval in 2027.
FineHeart and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
Industry
HealthMedical devices
- Focus
- Cardiovascular devices
- Technologies
- Implantable devices
- Wireless power transfer
- Keywords
- Heart failure
- Heart pumps
- Cardiac support
- Ventricular assist devices